Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Adalimumab in Subjects With Peripheral Spondyloarthritis

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: February 5, 2010
Last updated: May 19, 2014
Last verified: May 2014
This study will study how well adalimumab works in the short and long term in subjects with peripheral spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.

Condition Intervention Phase
Peripheral Spondyloarthritis
Biological: adalimumab
Biological: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Primary Outcome Measure [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Response of: >/= 40% improvement from Baseline in Patient Global Assessment of Disease Activity, Patient Global Assessment of Pain and at least 1 of the following 3 criteria: Swollen Joint & Tender Joint Count, Enthesitis Count and Dactylitis Count

  • Adverse Events [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Physician's Global Assessment of Disease Activity (VAS) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Bath AS Disease Activity Index (BASDAI) Score & SF-36 v2 physical component [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • Health Assessment Questionnaire modified for the Spondyloarthropathies (HAQ-S) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]

Enrollment: 165
Study Start Date: February 2010
Study Completion Date: May 2014
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: adalimumab- double blind Biological: adalimumab
40mg subcutaneous injection every other week up to week 12
Other Name: ABT-D2E7 Humira
Placebo Comparator: placebo - double blind Biological: placebo
placebo subcutaneous injection every other week up to week 12
Experimental: adalimumab - open label Biological: adalimumab
40mg subcutaneous injection every other week, week 12 thru week 156
Other Name: ABT-D2E7 Humira


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult subjects with inadequate response to >/= 2 non-steroidal anti-inflammatories (NSAIDs)
  • Subjects must have current arthritis or enthesitis dactylitis PLUS: meeting spondyloarthritis clinical criteria
  • Negative purified protein derivative (PPD) test and Chest X-Ray performed at Baseline Visit must be Negative
  • Ability to administer subcutaneous injections
  • General good health otherwise

Exclusion Criteria:

  • Prior anti-tumor necrosis factor (TNF) therapy
  • Psoriasis or Psoriatic Arthritis
  • Fulfillment of modified New York criteria for Ankylosing Spondylitis
  • Recent infection requiring treatment
  • Significant medical events or conditions that may put patients at risk for participation
  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
  • History of cancer, except successfully treated skin cancer
  • Recent history of drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01064856

  Hide Study Locations
United States, Nebraska
Site Reference ID/Investigator# 37462
Lincoln, Nebraska, United States, 68515
United States, Ohio
Site Reference ID/Investigator# 38693
Cleveland, Ohio, United States, 44109-1998
United States, Pennsylvania
Site Reference ID/Investigator# 26351
Duncansville, Pennsylvania, United States, 16635
United States, Tennessee
Site Reference ID/Investigator# 26366
Chattanooga, Tennessee, United States, 37404
United States, Washington
Site Reference ID/Investigator# 26353
Seattle, Washington, United States, 98104
United States, West Virginia
Site Reference ID/Investigator# 26756
Clarksburg, West Virginia, United States, 26301
Site Reference ID/Investigator# 37361
Hobart, Australia, 7001
Site Reference ID/Investigator# 26667
Malvern East, Australia, 3145
Site Reference ID/Investigator# 26669
Maroochydore, Australia, 4558
Site Reference ID/Investigator# 26671
Shenton Park, Australia, 6008
Site Reference ID/Investigator# 26663
Genk, Belgium, 3600
Site Reference ID/Investigator# 26672
Gent, Belgium, 9000
Site Reference ID/Investigator# 26664
Gilly, Belgium, 6060
Site Reference ID/Investigator# 26665
Montreal, Canada, H2L 1S6
Site Reference ID/Investigator# 26674
St. John's, Canada, A1C 5B8
Site Reference ID/Investigator# 26675
Winnipeg, Canada, R3N OK6
Czech Republic
Site Reference ID/Investigator# 29764
Brno, Czech Republic, 638 00
Site Reference ID/Investigator# 37070
Pardubice, Czech Republic, 530 02
Site Reference ID/Investigator# 29763
Prague 2, Czech Republic, 128 50
Site Reference ID/Investigator# 29762
Uherske Hradiste, Czech Republic, 686 01
Site Reference ID/Investigator# 27842
Amiens, France, 80054
Site Reference ID/Investigator# 26678
Chambray-les-Tour, France, 37170
Site Reference ID/Investigator# 26677
Paris Cedex 14, France, 75679
Site Reference ID/Investigator# 26680
Berlin, Germany, 12200
Site Reference ID/Investigator# 26679
Herne, Germany, 44649
Site Reference ID/Investigator# 26681
Zerbst, Germany, 39261
Site Reference ID/Investigator# 26682
Heraklion Crete, Greece, 70013
Site Reference ID/Investigator# 26683
Thessaloniki, Greece, 54636
Site Reference ID/Investigator# 26685
Debrecen, Hungary, H-4032
Site Reference ID/Investigator# 26684
Szeged, Hungary, H-6725
Site Reference ID/Investigator# 26688
Cork, Ireland
Site Reference ID/Investigator# 26687
Dublin 4, Ireland
Site Reference ID/Investigator# 27504
Barcelona, Spain, 08036
Site Reference ID/Investigator# 26690
Cordoba, Spain, 14004
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: In-Ho Song, MD AbbVie
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01064856     History of Changes
Other Study ID Numbers: M10-883  2009-014567-39 
Study First Received: February 5, 2010
Last Updated: May 19, 2014
Health Authority: Australia: Human Research Ethics Committee
Belgium: Federal Agency for Medicinal Products and Health Products
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Czech Republic: State Institute for Drug Control
United States: Food and Drug Administration
Germany: Paul-Ehrlich-Institut
Greece: National Organization of Medicines
Hungary: National Institute of Pharmacy
Ireland: Irish Medicines Board
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by AbbVie:
peripheral spondyloarthritis

Additional relevant MeSH terms:
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Joint Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 30, 2016